Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lucid Diagnostics Inc (NQ: LUCD )

1.400 +0.010 (+0.72%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 695,430
Open 1.400
Bid (Size) 1.360 (2)
Ask (Size) 1.480 (1)
Prev. Close 1.390
Today's Range 1.310 - 1.610
52wk Range 1.105 - 3.640
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Lucid Diagnostics Earnings Perspective: Return On Capital Employed
 
Via Benzinga

Performance

YTD
+0.72%
+0.72%
1 Month
+2.94%
+2.94%
3 Month
+2.94%
+2.94%
6 Month
-8.50%
-8.50%
1 Year
-58.33%
-58.33%

More News

Read More
A Preview Of Lucid Diagnostics's Earnings
Via Benzinga
Why PAVmed Shares Are Falling Today
Via Benzinga
PAVmed, Lucid Diagnostics Pause Some Development Programs, Announce Layoffs
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
PAVmed and Lucid Diagnostics Provide Strategic Business Update
From PAVmed Inc.
Via Business Wire
PAVmed and Lucid Diagnostics to Provide Strategic Business Update
From PAVmed Inc.
Via Business Wire
PAVmed Partners with Novosound on Ultrasound Imaging Technology
From PAVmed Inc.
Via Business Wire
Lucid Diagnostics Selected as Finalist for Medtech Company of the Year 2022 by Medical Device + Diagnostic Industry
From Lucid Diagnostics Inc.
Via Business Wire
PAVmed Digital Health Subsidiary Veris Health Launches Veris Cancer Care Platform
From PAVmed Inc.
Via Business Wire
Lucid Diagnostics Presents Real-World EsoCheck Data at the American Association for Cancer Research
From Lucid Diagnostics Inc.
Via Business Wire
PAVmed Provides Business Update and Third Quarter 2022 Financial Results
From PAVmed Inc.
Via Business Wire
Lucid Diagnostics Provides Business Update and Third Quarter 2022 Financial Results
From Lucid Diagnostics Inc.
Via Business Wire
Lucid Diagnostics to Participate in Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services Forum
From Lucid Diagnostics Inc.
Via Business Wire
Lucid Diagnostics Commences Production of EsoCheck Devices with High-Volume Manufacturer
From Lucid Diagnostics Inc.
Via Business Wire
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 14, 2022
From Lucid Diagnostics Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Lucid Diagnostics Provides Business Update and Preliminary Second Quarter 2022 Financial Results
From Lucid Diagnostics Inc.
Via Business Wire
Lucid Diagnostics Launches Stage II Lucid Test Center Expansion in California, Texas, Florida, and Ohio
From Lucid Diagnostics Inc.
Via Business Wire
Newly Published American Gastroenterological Association Clinical Practice Update Supports Esophageal Precancer Screening Using Lucid Diagnostics’ EsoGuard® and EsoCheck® Technologies
From Lucid Diagnostics Inc.
Via Business Wire
Lucid Diagnostics’ Laboratory Executes Four New Participating Provider Agreements
From Lucid Diagnostics Inc.
Via Business Wire
Lucid Diagnostics to Hold a Business Update Conference Call on August 15, 2022
From Lucid Diagnostics Inc.
Via Business Wire
Lucid Diagnostics to Participate in the Canaccord 42nd Annual Growth Conference and the 7th Annual Needham Med Tech & Diagnostics 1x1 Conference
From Lucid Diagnostics Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.